157 related articles for article (PubMed ID: 8957091)
1. Restoration of the transcription activation function to mutant p53 in human cancer cells.
AbarzĂșa P; LoSardo JE; Gubler ML; Spathis R; Lu YA; Felix A; Neri A
Oncogene; 1996 Dec; 13(11):2477-82. PubMed ID: 8957091
[TBL] [Abstract][Full Text] [Related]
2. Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53.
AbarzĂșa P; LoSardo JE; Gubler ML; Neri A
Cancer Res; 1995 Aug; 55(16):3490-4. PubMed ID: 7627952
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
4. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
Inga A; Resnick MA
Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
[TBL] [Abstract][Full Text] [Related]
5. Specific DNA binding by different classes of human p53 mutants.
Rolley N; Butcher S; Milner J
Oncogene; 1995 Aug; 11(4):763-70. PubMed ID: 7651740
[TBL] [Abstract][Full Text] [Related]
6. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
[TBL] [Abstract][Full Text] [Related]
7. Elevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53.
Loging WT; Reisman D
Cancer Epidemiol Biomarkers Prev; 1999 Nov; 8(11):1011-6. PubMed ID: 10566557
[TBL] [Abstract][Full Text] [Related]
8. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.
de Vries A; Flores ER; Miranda B; Hsieh HM; van Oostrom CT; Sage J; Jacks T
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2948-53. PubMed ID: 11867759
[TBL] [Abstract][Full Text] [Related]
9. Activation of p53 DNA binding activity by point mutation.
Marston NJ; Ludwig RL; Vousden KH
Oncogene; 1998 Jun; 16(24):3123-31. PubMed ID: 9671391
[TBL] [Abstract][Full Text] [Related]
10. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay.
Di Como CJ; Prives C
Oncogene; 1998 May; 16(19):2527-39. PubMed ID: 9627118
[TBL] [Abstract][Full Text] [Related]
11. Novel DNA binding of p53 mutants and their role in transcriptional activation.
Zhang W; Funk WD; Wright WE; Shay JW; Deisseroth AB
Oncogene; 1993 Sep; 8(9):2555-9. PubMed ID: 8361764
[TBL] [Abstract][Full Text] [Related]
12. 9-Hydroxyellipticine alters the conformation and DNA binding characteristics of mutated p53 protein.
Sugikawa E; Tsunoda S; Nakanishi N; Ohashi M
Anticancer Res; 2001; 21(4A):2671-5. PubMed ID: 11724337
[TBL] [Abstract][Full Text] [Related]
13. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.
Takimoto R; El-Deiry WS
Oncogene; 2000 Mar; 19(14):1735-43. PubMed ID: 10777207
[TBL] [Abstract][Full Text] [Related]
14. p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence.
Niewolik D; Vojtesek B; Kovarik J
Oncogene; 1995 Mar; 10(5):881-90. PubMed ID: 7898929
[TBL] [Abstract][Full Text] [Related]
15. TAR1, a human anti-p53 single-chain antibody, restores tumor suppressor function to mutant p53 variants.
Orgad S; Dimant H; Dor-On E; Azriel-Rosenfeld R; Benhar I; Solomon B
J Immunother; 2010; 33(2):146-54. PubMed ID: 20139776
[TBL] [Abstract][Full Text] [Related]
16. Characterisation of DNA binding and transcriptional regulatory function of an endogenous mutant p53 in MDA-468 human breast cancer cells.
Prasad KA; Church JG
Biochem Biophys Res Commun; 1997 Mar; 232(1):14-9. PubMed ID: 9125118
[TBL] [Abstract][Full Text] [Related]
17. Reactivation of mutant p53: molecular mechanisms and therapeutic potential.
Selivanova G; Wiman KG
Oncogene; 2007 Apr; 26(15):2243-54. PubMed ID: 17401433
[TBL] [Abstract][Full Text] [Related]
18. Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis.
Kato S; Han SY; Liu W; Otsuka K; Shibata H; Kanamaru R; Ishioka C
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8424-9. PubMed ID: 12826609
[TBL] [Abstract][Full Text] [Related]
19. Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil.
Pugacheva EN; Ivanov AV; Kravchenko JE; Kopnin BP; Levine AJ; Chumakov PM
Oncogene; 2002 Jul; 21(30):4595-600. PubMed ID: 12096336
[TBL] [Abstract][Full Text] [Related]
20. Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity.
Brazda V; Muller P; Brozkova K; Vojtesek B
Biochem Biophys Res Commun; 2006 Dec; 351(2):499-506. PubMed ID: 17070499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]